Anderson et al. (2018) [39] demonstrated that cancer cells with mutations in the isocitrate dehydrogenase gene (IDH) become less sensitive (or insensitive) to treatment with “modified” isocitrate dehydrogenase (IDH) inhibitors. This evidence concerns the gene IDH3A and cancer.